Characterizing Vancomycin-Resistant C. difficile Strains at Two Geographically Distinct Locations
两个不同地理位置的耐万古霉素艰难梭菌菌株的特征
基本信息
- 批准号:10595072
- 负责人:
- 金额:$ 66.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AfricanAntibiotic TherapyAntibioticsBiochemicalCessation of lifeClassificationClinicalClostridium difficileCommunicable DiseasesDiarrheaElementsEpidemiologyExhibitsFecesFoundationsGene ClusterGenesGeneticGenomicsGeographyGoalsGuidelinesHealthcareHomologous GeneHospitalsIncidenceInfectionInterventionKenyaLifeLocationMediatingMediatorMetronidazoleNorth AmericaOralOutcomePatientsPeptidoglycanPharmaceutical PreparationsPredispositionPrevention strategyPublic HealthPulsed-Field Gel ElectrophoresisRecommendationRecurrenceReportingResearchResistanceRibotypesSeverity of illnessSocietiesTexasTreatment FailureVancomycinVancomycin ResistanceWorkalternative treatmentantibiotic-associated diarrheabasecostgenetic elementgenome sequencinginsightmortalitypathogenpatient populationprospectiverecurrent infectionresistance mechanismresistant strainstool sampletreatment responsewhole genome
项目摘要
PROJECT SUMMARY
Clostridioides difficile infection (CDI) is the leading cause of antibiotic-associated diarrhea and death worldwide. As
a result, the U.S. CDC has classified C. difficile (CD) as an urgent public health threat. Recent guidelines from
Infectious Diseases Society of America and Society for Healthcare Epidemiology of America recommended oral
vancomycin or fidaxomicin for both non-severe and severe CDI cases. Because of the high cost of fidaxomicin,
vancomycin is now the drug of choice, making it the most important antibiotic for the treatment of CDI.
The foundation for this work is based on our recent discovery of CD strains in patients from Texas and
Kenya exhibiting reduced susceptibility to both metronidazole and vancomycin. We examined diarrhea CDI
stools from 438 patients from Texas and 98 from Kenya for the presence of metronidazole- and vancomycin-non-
susceptible CD isolates. Of the stools from Houston, 114/438 (26%) grew CD isolates that were not susceptible to
vancomycin, 128/438 (29%) to metronidazole, and 97/438 (22%) to both metronidazole and vancomycin. Among
the Kenyan patients, 66/98 (67%) were not susceptible to vancomycin, 83/98 (85%) to metronidazole, and 57/98
(58%) to both antibiotics. Alarmingly, many of the isolates from both locations showed levels of non-susceptibility to
these antibiotics that far exceeded their known MICs. Whole-genome sequencing showed the presence of
homologs of vanA and vanB gene clusters, common mediators of high-level vancomycin resistance in many
hospital-associated pathogens. Until now, such high-level vancomycin non-susceptibility has not been reported in
CD strains. The spread of CD strains resistant to vancomycin, a front-line antibiotic for this life-threatening
pathogen, will have serious clinical and public health implications. This underscores an urgent need for a
comprehensive analysis of the circulating strains, mechanisms of resistance, and how it impacts clinical outcomes
to help inform clinical decisions. Our preliminary evidence strongly supports the hypothesis that vancomycin
non-susceptible CD strains may be widespread in the CDI patient population and that strains circulating on
the African continent may be genetically different from strains circulating in North America. To investigate
this hypothesis, we will (i) assess the proportion of CDI patients from Texas and Kenya infected with vancomycin
non-susceptible strains and compare the infecting strains; (ii) characterize the genetic elements associated with
vancomycin non-susceptibility; and (iii) prospectively follow CDI patients infected with vancomycin non-susceptible
strains to assess disease severity, clinical outcome, and rate of recurrence of the infection following treatment.
Due to the current importance of vancomycin in CDI treatment, the proposed research will have a major
impact on clinical decisions. Importantly, the genetic elements responsible for high-level vancomycin non-
susceptibility in CD strains and how it impacts disease severity, clinical outcome, and treatment will be
established. This will provide insight into the extent of resistance and open up new avenues for long-term
preventative and interventional strategies to mitigate deaths associated with this life-threatening pathogen.
项目总结
艰难梭状芽胞杆菌感染(CDI)是全球抗生素相关性腹泻和死亡的主要原因。AS
因此,美国疾控中心已将艰难梭菌(CD)列为紧急公共卫生威胁。最近的指导方针来自
美国传染病学会和美国保健流行病学学会推荐口服
对于非重症和重型CDI患者,万古霉素或非达克索米星均有效。由于非达克索米星的价格很高,
万古霉素现在是治疗CDI的首选药物,使其成为治疗CDI最重要的抗生素。
这项工作的基础是我们最近在德克萨斯州和澳大利亚的患者中发现的CD菌株
肯尼亚对甲硝唑和万古霉素的敏感性降低。我们检查了腹泻CDI
从德克萨斯州的438名患者和肯尼亚的98名患者的粪便中检测甲硝唑-和万古霉素-非...
敏感的CD分离株。在来自休斯顿的粪便中,114/438(26%)的人培养出不容易感染的CD分离株
甲硝唑耐药率为29%(128/438),甲硝唑与万古霉素同时耐药率为22%(97/438)。其中
肯尼亚患者中,66/98(67%)对万古霉素不敏感,83/98(85%)对甲硝唑不敏感,57/98
对两种抗生素的耐药率均为58%。令人担忧的是,来自这两个地点的许多分离株都显示出对
这些抗生素远远超过了它们已知的最低抑菌浓度。全基因组测序显示
Vana和vanB基因簇的同源物,许多万古霉素高水平耐药性的常见介体
与医院有关的病原体。到目前为止,还没有报道过如此高水平的万古霉素不敏感
CD菌株。对万古霉素耐药的CD菌株的传播,万古霉素是这种危及生命的一线抗生素
病原体,将有严重的临床和公共卫生影响。这突显出迫切需要一种
综合分析循环菌株、耐药机制及其对临床结局的影响
帮助为临床决策提供信息。我们的初步证据有力地支持了万古霉素
不敏感的CD毒株可能在CDI患者人群中广泛传播,而且这种毒株在
非洲大陆可能与北美流行的病毒株在基因上不同。去调查
在这一假设下,我们将(I)评估德克萨斯州和肯尼亚的CDI患者感染万古霉素的比例
不敏感的菌株并比较感染菌株;(Ii)鉴定与
万古霉素不敏感;以及(Iii)前瞻性跟踪感染万古霉素不敏感的CDI患者
评估疾病严重程度、临床结果和治疗后感染复发率的菌株。
由于目前万古霉素在CDI治疗中的重要性,拟议的研究将有一个主要的
对临床决策的影响。重要的是,负责高水平万古霉素的遗传因素非
CD菌株的敏感性及其对疾病严重性、临床结果和治疗的影响将是
已经成立了。这将提供对阻力程度的洞察,并开辟长期的新途径
预防和干预战略,以减少与这种威胁生命的病原体相关的死亡。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Darkoh其他文献
Charles Darkoh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles Darkoh', 18)}}的其他基金
Characterizing Vancomycin-Resistant C. difficile Strains at Two Geographically Distinct Locations
两个不同地理位置的耐万古霉素艰难梭菌菌株的特征
- 批准号:
10380182 - 财政年份:2021
- 资助金额:
$ 66.8万 - 项目类别:
Characterizing Vancomycin-Resistant C. difficile Strains at Two Geographically Distinct Locations
两个不同地理位置的耐万古霉素艰难梭菌菌株的特征
- 批准号:
10211571 - 财政年份:2021
- 资助金额:
$ 66.8万 - 项目类别:
Targeting the Toxins: A Novel Non-Antimicrobial Approach to Combat Clostridium difficile infections
针对毒素:对抗艰难梭菌感染的新型非抗菌方法
- 批准号:
9089989 - 财政年份:2015
- 资助金额:
$ 66.8万 - 项目类别:
相似海外基金
SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
- 批准号:
2213034 - 财政年份:2023
- 资助金额:
$ 66.8万 - 项目类别:
Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
- 批准号:
10645528 - 财政年份:2023
- 资助金额:
$ 66.8万 - 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
- 批准号:
10736285 - 财政年份:2023
- 资助金额:
$ 66.8万 - 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
- 批准号:
10603486 - 财政年份:2023
- 资助金额:
$ 66.8万 - 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
- 批准号:
449379 - 财政年份:2020
- 资助金额:
$ 66.8万 - 项目类别:
Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
- 批准号:
422034 - 财政年份:2020
- 资助金额:
$ 66.8万 - 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
- 批准号:
nhmrc : 1197866 - 财政年份:2020
- 资助金额:
$ 66.8万 - 项目类别:
Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
- 批准号:
2241853 - 财政年份:2019
- 资助金额:
$ 66.8万 - 项目类别:
Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
- 批准号:
18K07106 - 财政年份:2018
- 资助金额:
$ 66.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
- 批准号:
9788269 - 财政年份:2018
- 资助金额:
$ 66.8万 - 项目类别: